Notice2024-10970
Prospective Grant of an Exclusive Patent License: T Cell Receptor Fusion Proteins for the Treatment of Cancer
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 20, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to INTcRON LLC ("INTcRON") located in Memphis, Tennessee.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 98 (Monday, May 20, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 98 (Monday, May 20, 2024)]
[Notices]
[Pages 43859-43860]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-10970]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: T Cell Receptor
Fusion Proteins for the Treatment of Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patents and Patent Applications listed in
the Supplementary Information section of this notice to INTcRON LLC
(``INTcRON'') located in Memphis, Tennessee.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before June 4, 2024 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer
Manager, NCI Technology Transfer Center, Telephone: (240) 276-5484;
Email: <a href="/cdn-cgi/l/email-protection#d0b1beb4a9feb2a5a2bbb590beb9b8feb7bfa6"><span class="__cf_email__" data-cfemail="3e5f505a47105c4b4c555b7e50575610595148">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. United States Provisional Patent Application No. 62/369,883
filed August 2, 2016, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS
Reference No. E-175-2016-0-US-01];
2. PCT Patent Application No. PCT/US2017/044615 filed July 31,
2017, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No.
E-175-2016-0-PCT-02];
3. Australian Patent No. 2017306038 issued October 5, 2023,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-AU-03];
4. Canadian Patent Application No. 3,032,870 effective filing date
of July 31,
[[Page 43860]]
2017, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No.
E-175-2016-0-CA-04];
5. Chinese Patent Application No. 201780059356.4 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-CN-05];
6. European Patent No. 3494133 issued July 6, 2022, entitled
``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-2016-0-EP-
06];
a. Validated in the following jurisdictions: AL, AT, BE, BG, CH,
CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, HR, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM and TR.
7. Japanese Patent Application No. 2019-505220 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-JP-07];
8. United States Patent No. 10,611,816 issued April 7, 2020,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-US-08];
9. Israeli Patent No. 264425 issued August 2, 2023, entitled
``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-2016-0-IL-
09];
10. South Korean Patent No. 10-2527052 issued April 25, 2023,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-KR-10];
11. Singapore Patent Application No. 11201900654Q effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-SG-11];
12. Hong Kong Patent No. HK40009637 issued July 7, 2023, entitled
``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-2016-0-HK-
12];
13. Hong Kong Patent Application No. 19132196.7 effective filing
date of July 31, 2017, entitled ``Anti-KRAS G12D T Cell Receptors''
[HHS Reference No. E-175-2016-0-HK-13];
14. Singapore Patent Application No. 10201913959W filed December
31, 2019, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference
No. E-175-2016-0-SG-14];
15. United States Patent No. 11,208,456 issued December 28, 2021,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-US-15];
16. United States Patent No. 11,897,933 issued February 13, 2024,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-US-16];
17. United States Patent No. 11,840,561 issued December 12, 2023,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-US-17];
18. Japanese Patent No. 7413338 issued January 4, 2024, entitled
``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-2016-0-JP-
18];
19. European Patent Application No. 22182473.3 filed July 1, 2022,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-EP-19];
20. Israeli Patent Application No. 301894 filed April 3, 2023,
entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No. E-175-
2016-0-IL-01];
21. Hong Kong Patent Application No. 42023078137.9 filed August 28,
2023, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No.
E-175-2016-0-HK-01];
22. Australian Patent Application No. 2023233125 filed September
21, 2023, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference
No. E-175-2016-0-AU-01];
23. Japanese Patent Application No. 2023-221526 filed December 27,
2023, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference No.
E-175-2016-0-JP-01];
24. United States Patent Application No. 18/423,020 filed January
25, 2024, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference
No. E-175-2016-0-US-02]; and
25. Chinese Patent Application No. 202410214235.4 filed February
27, 2024, entitled ``Anti-KRAS G12D T Cell Receptors'' [HHS Reference
No. E-175-2016-0-CN-01].
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the following:
``Development, manufacture and commercialization of acellular
fusion protein therapy products for the treatment of cancer in humans,
wherein:
1. The fusion protein contains at least the antigen binding domain
of either T cell receptor (TCR) ``TRAV12-2/TRBV10/2'' or ``TRAV4/TRBV5-
6 (A, B or C)'', as disclosed and claimed in the Licensed Patent
Rights;
2. The cancer expresses mutant KRAS G12D; and
3. The human(s) express(es) at least HLA-C*08:02 or HLA-C*05:01.
For the avoidance of doubt, specifically excluded from this
Licensed Field of Use are cell therapy products (e.g., T cell or
natural killer cell-based) which have been genetically engineered to
express the TCR(s) claimed in the Licensed Patent Rights.''
The Intellectual Property is primarily directed to isolated T cell
receptors (TCRs) reactive to mutated Kirsten rat sarcoma viral oncogene
homolog (KRAS), within the context of human leukocyte antigens (HLAs)
C*08:02 or C*05:01. Mutated KRAS, which plays a well-defined driver
role in oncogenesis, is expressed by a variety of human cancers,
including pancreatic, lung, endometrial, ovarian and prostate. Due to
its restricted expression in precancerous and cancerous cells, this
antigen may be targeted on mutant KRAS-expressing tumors with minimal
normal tissue toxicity.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: May 15, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2024-10970 Filed 5-17-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 20, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.